The Clinical Impact of β-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention

다국어 초록 (Multilingual Abstract)

Background and Objectives: The outcome benefits of β-blockers in chronic coronary artery disease (CAD) have not been fully assessed. We evaluated the prognostic impact of β-blockers on patients with chronic CAD after percutaneous coronary intervention (PCI).
Methods: A total of 3,075 patients with chronic CAD were included from the Grand Drug-Eluting Stent registry. We analyzed β-blocker prescriptions, including doses and types, in each patient at 3-month intervals from discharge. After propensity score matching, 1,170 pairs of patients (β-blockers vs. no β-blockers) were derived. Primary outcome was defined as a composite endpoint of all-cause death and myocardial infarction (MI). We further analyzed the outcome benefits of different doses (low-, medium-, and high-dose) and types (conventional or vasodilating) of β-blockers.
Results: During a median (interquartile range) follow-up of 3.1 (3.0–3.1) years, 134 (5.7%) patients experienced primary outcome. Overall, β-blockers demonstrated no significant benefit in primary outcome (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.63–1.24), all-cause death (HR, 0.87; 95% CI, 0.60–1.25), and MI (HR, 1.25; 95% CI, 0.49–3.15). In subgroup analysis, β-blockers were associated with a lower risk of all-cause death in patients with previous MI and/or revascularization (HR, 0.38; 95% CI, 0.14–0.99) (p for interaction=0.045). No significant associations were found for the clinical outcomes with different doses and types of β-blockers.
Conclusions: Overall, β-blocker therapy was not associated with better clinical outcomes in patients with chronic CAD undergoing PCI. Limited mortality benefit of β-blockers may exist for patients with previous MI and/or revascularization.

참고문헌 (Reference)

1 Ambrosio G, "β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure" 97 : 209-214, 2011

2 Sorbets E, "β-Blockers, calcium antagonists, and mortality in stable coronary artery disease : an international cohort study" 40 : 1399-1407, 2019

3 Bangalore S, "β-Blockers and cardiovascular events in patients with and without myocardial infarction : post hoc analysis from the CHARISMA trial" 7 : 872-881, 2014

4 Bangalore S, "β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease" 308 : 1340-1349, 2012

5 Andersson C, "β-Blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease" 64 : 247-252, 2014

6 Puymirat E, "β blockers and mortality after myocardial infarction in patients without heart failure : multicentre prospective cohort study" 354 : i4801-, 2016

7 Viskin S, "Treatment with beta-adrenergic blocking agents after myocardial infarction : from randomized trials to clinical practice" 25 : 1327-1332, 1995

8 "The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial" 353 : 9-13, 1999

9 Parsons LS, "Reducing bias in a propensity score matched-pair sample using greedy matching techniques" SAS User Groups 2001

10 Hwang D, "Prognostic impact of β-blocker dose after acute myocardial infarction" 83 : 410-417, 2019

11 Motivala AA, "Predictors, trends, and outcomes(among older patients ≥65 years of age)associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention : insights from the NCDR registry" 9 : 1639-1648, 2016

12 Park J, "Optimal dose and type of β-blockers in patients with acute coronary syndrome undergoing percutaneous coronary intervention" 137 : 12-19, 2020

13 Diaz A, "Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease" 26 : 967-974, 2005

14 Jaehoon Chung ; Jung-Kyu Han ; Han-Mo Yang ; Kyung-Woo Park ; Hyun-Jae Kang ; Bon-Kwon Koo ; Myung Ho Jeong ; Hyo-Soo Kim, "Long-term efficacy of vasodilating β-blocker in patients with acute myocardial infarction: nationwide multicenter prospective registry" 대한내과학회 36 : 62-71, 2021

15 Fonseca VA, "Effects of beta-blockers on glucose and lipid metabolism" 26 : 615-629, 2010

16 Hjalmarson A, "Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial" 2 : 823-827, 1981

17 Dahl Aarvik M, "Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients : a systematic review and meta-analysis" 5 : 12-20, 2019

18 Packer M, "Effect of carvedilol on survival in severe chronic heart failure" 344 : 1651-1658, 2001

19 Dargie HJ, "Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomised trial" 357 : 1385-1390, 2001

20 Goldberger JJ, "Effect of beta-blocker dose on survival after acute myocardial infarction" 66 : 1431-1441, 2015

21 Narahara KA, "Double-blind comparison of once daily betaxolol versus propranolol four times daily in stable angina pectoris" 65 : 577-582, 1990

22 Rodrigues EA, "Comparison of bevantolol and atenolol in chronic stable angina" 61 : 1204-1209, 1988

23 Johnston DL, "Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina : a double-blind, placebo-controlled, randomized, crossover study with radionuclide ventriculography" 68 : 1280-1289, 1983

24 Bangalore S, "Clinical outcomes with β-blockers for myocardial infarction : a meta-analysis of randomized trials" 127 : 939-953, 2014

25 McEniery CM, "Central blood pressure : current evidence and clinical importance" 35 : 1719-1725, 2014

26 Leizorovicz A, "Bisoprolol for the treatment of chronic heart failure : a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study" 143 : 301-307, 2002

27 Chung J, "Benefit of vasodilating β-blockers in patients with acute myocardial infarction after percutaneous coronary intervention : nationwide multicenter cohort study" 6 : e007063-, 2017

28 Austin PC, "Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples" 28 : 3083-3107, 2009

29 Knuuti J, "2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes" 41 : 407-477, 2020